Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05676034 · ClinicalTrials.gov registry record · Phase 2
AMX0035 in Adult Patients With Wolfram Syndrome
A Phase 2 study of Wolfram Syndrome, sponsored by Amylyx Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05676034 is a Phase 2 study of Wolfram Syndrome that is active but no longer recruiting, run by Amylyx Pharmaceuticals. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05676034, a Phase 2 study of Wolfram Syndrome, is active but no longer recruiting, sponsored by Amylyx Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
Conditions Studied
Interventions
- DRUG AMX0035
Study Locations (1)
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-03-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05676034
The ClinicalTrials.gov registry entry for NCT05676034 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amylyx Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wolfram Syndrome appearing as the primary indexed condition, and to 1 intervention - of which AMX0035 is the first listed.
NCT05676034 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05676034 about?
NCT05676034 is a clinical study titled "AMX0035 in Adult Patients With Wolfram Syndrome". This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
What is the current status of trial NCT05676034?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-03-03. Estimated completion is 2026-12-31.
What conditions does trial NCT05676034 study?
This clinical trial studies the following conditions: Wolfram Syndrome.
What interventions are being tested in trial NCT05676034?
The interventions under investigation include: AMX0035 (DRUG).
Who is sponsoring clinical trial NCT05676034?
This trial is sponsored by Amylyx Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05676034 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wolfram Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.